Edwards Lifesciences
691 hedge funds and large institutions have $16.6B invested in Edwards Lifesciences in 2017 Q1 according to their latest regulatory filings, with 100 funds opening new positions, 207 increasing their positions, 284 reducing their positions, and 83 closing their positions.
20% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 83
1% more funds holding
Funds holding: 686 → 691 (+5)
2% less capital invested
Capital invested by funds: $16.9B → $16.6B (-$297M)
3.99% less ownership
Funds ownership: 253.21% → 249.22% (-4%)
27% less repeat investments, than reductions
Existing positions increased: 207 | Existing positions reduced: 284
33% less call options, than puts
Call options by funds: $72.1M | Put options by funds: $108M
50% less funds holding in top 10
Funds holding in top 10: 14 → 7 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.26B |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$228M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$137M |
| 4 |
HM
HealthCor Management
New York
|
+$117M |
| 5 |
WP
Wedgewood Partners
St Louis,
Missouri
|
+$107M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$496M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$346M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$125M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$89.6M |
| 5 |
CCI
Columbus Circle Investors
|
-$83.4M |
EW Hedge Fund Activity: Q1 2017 in Review
691 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2017, worth a combined $16.6B — down 1.8% from $16.9B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new EW positions and 83 closed out — a net gain of 17 holders — while 207 added to existing stakes and 284 trimmed.
The largest buyer was BlackRock, adding an estimated $1.26B. The largest seller was Fidelity Investments, cutting an estimated $496M.
- 691 institutional investors held Edwards Lifesciences (EW) as of Q1 2017, up from 686 in Q4 2016.
- Funds reported $16.6B of Edwards Lifesciences stock for Q1 2017, down 1.8% quarter-over-quarter.
- 100 funds opened new Edwards Lifesciences positions in Q1 2017 and 83 closed out, a net change of +17 holders.
- The largest Edwards Lifesciences buyer in Q1 2017 was BlackRock, an estimated $1.26B added.
- The largest Edwards Lifesciences seller in Q1 2017 was Fidelity Investments, an estimated $496M sold.
Based on aggregated 13F filings for Q1 2017.